Mary Hitchcock Memorial Hosp
- Type
- Teaching hospital
- Where
- Lebanon, NH
- Medicare CCN
- 300003
- Received
- $3,554,765 in 418 records, 2022 ($1,075,775 general, $2,478,990 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 128 | $1,075,775 |
| 2022 | Research payment | 290 | $2,478,990 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 290 | $2,478,990 |
| Consulting Fee | 12 | $926,667 |
| Grant | 4 | $68,000 |
| Long term medical supply or device loan | 94 | $43,108 |
| Space rental or facility fees (teaching hospital only) | 15 | $33,000 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $2,500 |
| Education | 1 | $2,500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Merck Sharp & Dohme LLC | $787,748 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01 Master Study A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $66,238 | Research payment | In-kind items and services | Biological, INFECTIOUS DISEASE | A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunoge | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $66,238 | Research payment | In-kind items and services | Biological, INFECTIOUS DISEASE | A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunoge | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $61,122 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2022 |
| 2022-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,283 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2022 |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $2,055 | Research payment | In-kind items and services | Dartmouth Hitchcock2022MRIPR816Weaver | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,902 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembro | 2022 |
| 2022-12-31 | Intuitive Surgical, Inc. | $1,807 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,768 | Research payment | In-kind items and services | Biological, INFECTIOUS DISEASE | A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunoge | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,736 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembro | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,577 | Research payment | In-kind items and services | Biological, INFECTIOUS DISEASE | A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunoge | 2022 |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $750 | Research payment | In-kind items and services | Dartmouth2019MRIPR758Weaver | 2022 | |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $257 | Research payment | In-kind items and services | MHMHDHC2021MRIPR1066Ford | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $149 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2022 |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $99 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $80 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $80 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Masimo Corporation | $6 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01Substudy 1 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combi | 2022 |
| 2022-12-29 | Medical Device Business Services, Inc. | $100 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2022 |
| 2022-12-19 | Merck Sharp & Dohme LLC | $214,173 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01 Master Study A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab | 2022 |
| 2022-12-19 | Masimo Corporation | $77,440 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-12-19 | Boston Scientific Corporation | $1,500 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-12-14 | VERTEX PHARMACEUTICALS INCORPORATED | $2,786 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With | 2022 | |
| 2022-12-12 | ABBVIE INC. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2022 | |
| 2022-12-12 | Smith+Nephew, Inc. | $333 | Long term medical supply or device loan | In-kind items and services | NA Device, Enabling Technology | 2022 | |
| 2022-12-09 | W. L. Gore & Associates, Inc. | $715 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | 'GREAT' Global Registry for Endovascular Aortic Treatment | 2022 |
| 2022-12-08 | Medtronic, Inc. | $572 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2022 |
| 2022-12-07 | Merck Sharp & Dohme LLC | $120,872 | Research payment | Cash or cash equivalent | Biological, INFECTIOUS DISEASE | A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunoge | 2022 |
| 2022-12-07 | Merck Sharp & Dohme LLC | $93,073 | Research payment | Cash or cash equivalent | Biological, INFECTIOUS DISEASE | A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunoge | 2022 |
| 2022-12-07 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-12-07 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-12-07 | Medical Device Business Services, Inc. | $50 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2022 |
| 2022-12-06 | Regeneron Pharmaceuticals, Inc. | $2,600 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO < | 2022 |
| 2022-12-06 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO < | 2022 |
| 2022-12-01 | Kaneka Medical America LLC | $295 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-11-28 | Masimo Corporation | $154,589 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-11-28 | Medical Device Business Services, Inc. | $10,230 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Attune Revision RTKA Population Multi Center Clinical Evaluation of the Attune Revision System in Complex Primary Total | 2022 |
| 2022-11-23 | Medtronic, Inc. | $273 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2022 |
| 2022-11-21 | Boston Scientific Corporation | $1,651 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAPTOO | 2022 |
| 2022-11-21 | Medtronic, Inc. | $747 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2022 |
| 2022-11-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $675 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously | 2022 |
| 2022-11-18 | Medical Device Business Services, Inc. | $596 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow up | 2022 |
| 2022-11-18 | W. L. Gore & Associates, Inc. | $65 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Throacoabdominal Branch Endoprothesis in the Treatment of Throacoabdominal and Pararenal | 2022 |
| 2022-11-17 | Philips North America LLC | $11,100 | Research payment | Cash or cash equivalent | (V064) SyncVision Device, Medical Device | Define GPS | 2022 |
| 2022-11-16 | Horizon Therapeutics plc | $18,450 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, REPEAT-DOSE, MULTICENTER TRIAL TO EVALUATE THE EFFICACY, SAFETY | 2022 | |
| 2022-11-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,160 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | Nintedanib in PF ILD extension | 2022 |
| 2022-11-16 | Fresenius Kabi USA, LLC | $700 | Research payment | Cash or cash equivalent | In Vitro and In Vivo Evaluation of an Alternate Filter for the Alyx A200 Leukoreduction Filter | 2022 | |
| 2022-11-14 | Edwards Lifesciences Corporation | $25,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-11-10 | PFIZER INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2022 | |
| 2022-11-09 | SANOFI PASTEUR INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-11-09 | Medical Device Business Services, Inc. | $832 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2022 |
| 2022-11-08 | Lilly USA, LLC | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-11-04 | Gentuity, LLC | $8,821 | Long term medical supply or device loan | In-kind items and services | Gentuity HF-OCT Imaging System Device, Vascular Imaging | 2022 | |
| 2022-11-04 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-11-04 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-11-03 | Ascendis Pharma Endocrinology Inc | $18,512 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | enliGHten | 2022 |
| 2022-11-03 | Ascendis Pharma Endocrinology Inc | $3,000 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | enliGHten | 2022 |
| 2022-11-03 | Edwards Lifesciences Corporation | $1,144 | Research payment | Cash or cash equivalent | CLASP II TR Pivotal, Study No. 2019-07 | 2022 | |
| 2022-11-03 | Edwards Lifesciences Corporation | $845 | Research payment | Cash or cash equivalent | CLASP II TR Pivotal, Study No. 2019-07 | 2022 | |
| 2022-11-02 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,000 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously | 2022 |
| 2022-11-01 | Boston Scientific Corporation | $8,000 | Grant | Cash or cash equivalent | GENERAL - CATHETER Device, CATHETERS | 2022 | |
| 2022-10-31 | Genentech, Inc. | $9,251 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2022 |
| 2022-10-31 | Medical Device Business Services, Inc. | $50 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2022 |
| 2022-10-27 | Medtronic, Inc. | $29,907 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2022 |
| 2022-10-27 | Genentech USA, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-10-27 | Medtronic, Inc. | $2,771 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2022 |
| 2022-10-26 | Fresenius Kabi USA, LLC | $2,500 | Research payment | Cash or cash equivalent | In Vitro and In Vivo Evaluation of an Alternate Filter for the Alyx A200 Leukoreduction Filter | 2022 | |
| 2022-10-26 | AstraZeneca Pharmaceuticals LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-10-26 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,405 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously | 2022 |
| 2022-10-20 | ABIOMED | $12,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | 2022 | |
| 2022-10-20 | Celgene Corporation | $1,000 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | Ph III Yellowstone CD Maintenance (RPC01-3203) - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled St | 2022 |
| 2022-10-17 | Boston Scientific Corporation | $1,353 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-10-17 | Boston Scientific Corporation | $598 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAPTOO | 2022 |
| 2022-10-10 | Edwards Lifesciences Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2022 | |
| 2022-10-06 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-10-04 | NEUROPACE, INC. | $400 | Research payment | Cash or cash equivalent | RNS Neurostimulator Kit Device, Epilepsy | Post Approval Study | 2022 |
| 2022-10-04 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS Neurostimulator Kit Device, Epilepsy | Post Approval Study | 2022 |
| 2022-10-04 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS Neurostimulator Kit Device, Epilepsy | Post Approval Study | 2022 |
| 2022-10-04 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS Neurostimulator Kit Device, Epilepsy | Post Approval Study | 2022 |
| 2022-10-04 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS Neurostimulator Kit Device, Epilepsy | Post Approval Study | 2022 |
| 2022-10-04 | NEUROPACE, INC. | $50 | Research payment | Cash or cash equivalent | RNS Neurostimulator Kit Device, Epilepsy | Post Approval Study | 2022 |
| 2022-09-30 | Intuitive Surgical, Inc. | $1,807 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2022 | |
| 2022-09-30 | Relievant Medsystems, Inc. | $552 | Research payment | Cash or cash equivalent | Intracept Device, Pain | Intracept | 2022 |
| 2022-09-27 | Eli Lilly and Company | $66 | Research payment | In-kind items and services | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 3 STUDY OF NONSTEROIDAL AROMATASE INHIBITORS -ANASTROZOLE OR LETROZOL | 2022 | |
| 2022-09-26 | Genentech USA, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-09-25 | AstraZeneca Pharmaceuticals LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ANDEXXA Biological, Rare Disease | 2022 | |
| 2022-09-23 | Medtronic, Inc. | $137 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2022 |
| 2022-09-21 | Masimo Corporation | $77,149 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-09-20 | Boston Scientific Corporation | $2,600 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | IMPERIAL | 2022 |
| 2022-09-20 | NEUROPACE, INC. | $1,500 | Research payment | Cash or cash equivalent | RNS Neurostimulator Kit Device, Epilepsy | Post Approval Study | 2022 |
| 2022-09-20 | NEUROPACE, INC. | $1,500 | Research payment | Cash or cash equivalent | RNS Neurostimulator Kit Device, Epilepsy | Post Approval Study | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $971 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-09-17 | Draeger Medical Systems, Inc | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BIRTHING ROOM WARMER Device, Neonatal Care & Warming Therapy | 2022 | |
| 2022-09-15 | Medtronic, Inc. | $25,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-09-15 | Medical Device Business Services, Inc. | $416 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2022 |
| 2022-09-14 | Gilead Sciences, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-09-13 | Medical Device Business Services, Inc. | $3,000 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2022 |
| 2022-09-13 | E.R. Squibb & Sons, L.L.C. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2022 | |
| 2022-09-12 | Medical Device Business Services, Inc. | $50 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Multi Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty | 2022 |
| 2022-09-08 | Medtronic, Inc. | $1,324 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2022 |
| 2022-09-07 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | Biological, INFECTIOUS DISEASE | A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, a | 2022 |
| 2022-09-06 | Boston Scientific Corporation | $1,293 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAPTOO | 2022 |
| 2022-09-06 | SOBI, INC | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SYNAGIS Drug, IMMUNOLOGY | 2022 | |
| 2022-09-06 | Medical Device Business Services, Inc. | $495 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Attune Revision RTKA Population Multi Center Clinical Evaluation of the Attune Revision System in Complex Primary Total | 2022 |
| 2022-08-26 | Janssen Research & Development, LLC | $466 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, Oncology | A Phase 3b Multi Center Open label PCI32765 Ibrutinib Long term Extension Study | 2022 |
| 2022-08-23 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,253 | Research payment | Cash or cash equivalent | ILUMYA Biological, Dermatology | Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously | 2022 |
| 2022-08-22 | Medical Device Business Services, Inc. | $883 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Attune Revision RTKA Population Multi Center Clinical Evaluation of the Attune Revision System in Complex Primary Total | 2022 |
| 2022-08-19 | Masimo Corporation | $77,149 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-19 | W. L. Gore & Associates, Inc. | $2,502 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | 'GREAT' Global Registry for Endovascular Aortic Treatment | 2022 |
| 2022-08-19 | W. L. Gore & Associates, Inc. | $130 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Throacoabdominal Branch Endoprothesis in the Treatment of Throacoabdominal and Pararenal | 2022 |
| 2022-08-18 | Masimo Corporation | $77,149 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-17 | Fresenius Kabi USA, LLC | $8,400 | Research payment | Cash or cash equivalent | In Vitro and In Vivo Evaluation of an Alternate Filter for the Alyx A200 Leukoreduction Filter | 2022 | |
| 2022-08-17 | Medtronic, Inc. | $377 | Research payment | Cash or cash equivalent | VISUALASE Device, MRI-guided laser ablation | SLATE | 2022 |
| 2022-08-16 | Medical Device Business Services, Inc. | $50 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow up | 2022 |
| 2022-08-15 | Masimo Corporation | $77,149 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-11 | VIEWRAY TECHNOLOGIES INC | $780 | Research payment | Cash or cash equivalent | MRIdian LINAC Device, Radiotherapy | Prospective Phase II Study of Stereotactic MR-guided ontable Adaptive Radiation Therapy for Patients with Borderline or | 2022 |
| 2022-08-10 | Ascendis Pharma Endocrinology Inc | $9,594 | Research payment | Cash or cash equivalent | SKYTROFA Drug, Endocrinology | enliGHten | 2022 |
| 2022-08-05 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-08-05 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-08-01 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | IMPERIAL | 2022 |
| 2022-08-01 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAPTOO | 2022 |
The latest 200 records of 418.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Lebanon, NH, county Grafton County, NH, state New Hampshire; placed by its city name.
| Measure | Place (city or town) Lebanon, NH | County Grafton County, NH | State New Hampshire |
|---|---|---|---|
| Population B01003 | 14,999 | 92,120 | 1,394,868 |
| Population, 2020 census P1 | 14,282 | 91,118 | 1,377,529 |
| Median age B01002 | 38.9 | 44.1 | 43.3 |
| Under 18 B01001 | 14.6% | 15.6% | 18.2% |
| 65 and over B01001 | 21.4% | 23.0% | 20.1% |
| Households B11001 | 6,917 | 37,107 | 555,822 |
| Foreign born B05002 | 8.6% | 5.6% | 6.1% |
| Median household income B19013 | $98,147 | $88,261 | $99,031 |
| Median family income B19113 | $120,046 | $109,351 | $122,715 |
| Per capita income B19301 | $56,599 | $52,790 | $52,798 |
| Poverty rate B17001 | 7.0% | 10.4% | 7.2% |
| Unemployment rate B23025 | 0.8% | 3.2% | 3.3% |
| Civilian labor force B23025 | 9,352 | 48,140 | 775,826 |
| Mean commute (minutes) B08013 | 14.0 | 22.2 | 26.7 |
| Bachelor's degree or higher B15003 | 57.5% | 46.7% | 40.6% |
| Housing units B25001 | 7,855 | 51,920 | 648,472 |
| Owner-occupied B25003 | 51.2% | 71.3% | 72.8% |
| Renters B25003 | 48.8% | 28.7% | 27.2% |
| Median home value B25077 | $385,400 | $344,500 | $402,500 |
| Median gross rent B25064 | $1,744 | $1,301 | $1,491 |
| White, not Hispanic B03002 | 84.3% | 87.5% | 86.9% |
| Black B03002 | 0.7% | 1.1% | 1.3% |
| Hispanic or Latino B03002 | 3.1% | 2.9% | 4.7% |
| Asian B03002 | 6.7% | 3.5% | 2.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Lebanon, NH.
Comments